Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.

Mercia Technologies has returned to back Warwick-founded medtech spinout Medherant, which is preparing to advance its adhesive Tepi Patch technology through the clinic.

AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.

The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

SoftBank China Venture Capital and Legend Capital contributed to a round that boosted the cancer screening device maker's overall funding to more than $100m.

Ideaya priced its shares below their range to raise $50m, providing exits for Alphabet, WuXi AppTec, Celgene, Roche and Novartis.

GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer based on Stanford research.

Mars has partnered Jerusalem Venture Partners in a venture that will involve them investing in Israel-based developers of food, agriculture and nutrition technologies.

The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.